What is the best course of treatment for a 14-year-old patient with adhenonia, anxiety, and social anxiety disorder, who always wants to hide their face?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 7, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Assessment and Treatment for a 14-Year-Old with Anhedonia, Anxiety, and Face-Hiding Behavior

This adolescent requires immediate assessment for Body Dysmorphic Disorder (BDD), as the face-hiding behavior is a classic presentation that is frequently misdiagnosed as social anxiety disorder alone, leading to suboptimal treatment. 1

Critical Diagnostic Consideration

Screen directly for appearance-related concerns, as young people with BDD rarely disclose these spontaneously but will respond if asked directly. 1 The combination of anxiety, anhedonia, and persistent face-hiding behavior strongly suggests BDD rather than isolated social anxiety disorder, particularly given the specific avoidance pattern. 1

Key Assessment Questions to Ask Directly

Ask the following questions to differentiate BDD from social anxiety disorder:

  • "Do you spend a lot of time worrying about how your face looks?" 1
  • "How much time during the day do you think about your appearance?" 1
  • "Do you avoid situations or try to hide your face because you're worried about how it looks?" 1
  • "Do you spend time comparing your face to others?" 1

Be vigilant for behavioral clues during assessment: wearing hoods, hats, or keeping the camera off during video sessions are red flags for BDD. 1

Treatment Algorithm

If BDD is Confirmed (Most Likely Scenario)

Start with specialized CBT for BDD combined with an SSRI (sertraline preferred for adolescents). 2, 3 The CBT must be BDD-specific, not generic anxiety treatment, as standard social anxiety protocols will be insufficient. 1

BDD-specific CBT components include: 1

  • Exposure and Response Prevention (ERP): Confronting social situations while resisting urges to hide the face or engage in checking behaviors 1
  • Behavioral experiments to test beliefs about appearance-related judgments 1
  • Mirror retraining to process appearance as a whole rather than fixating on perceived flaws 1
  • Eliminating safety behaviors like covering the face, excessive grooming, or reassurance-seeking 1

Pharmacotherapy: 2, 3

  • Start sertraline 25-50 mg daily, titrating slowly based on response 2
  • SSRIs are first-line for both BDD and comorbid anxiety 3
  • Expect 10-12 weeks for full therapeutic response 3

If Social Anxiety Disorder Without BDD

Begin with individual CBT specifically designed for social anxiety disorder, focusing on exposure therapy and cognitive restructuring. 2 Individual sessions are superior to group therapy for adolescents. 2

Add an SSRI if CBT alone is insufficient or symptoms are severe: 2

  • Sertraline or escitalopram are preferred due to favorable safety profiles 2, 3
  • Start at lower doses than adults and titrate slowly 2

Addressing Anhedonia

The anhedonia component requires specific attention, as traditional SSRIs may have limited benefit or even worsen anhedonia in some patients. 4 Consider:

  • Behavioral activation as part of CBT to address social withdrawal and low motivation 4
  • If anhedonia persists despite SSRI treatment, consider switching to vortioxetine or agomelatine, which show superior efficacy for anhedonia 4
  • Anhedonia is an independent risk factor for suicidality and requires careful monitoring 4

Critical Assessment Components

Conduct comprehensive suicide risk assessment, as adolescents with anxiety disorders have 24% prevalence of suicidal ideation and 6% attempt rate. 1 The combination of anxiety, anhedonia, and potential BDD significantly elevates this risk. 1, 4

Assess for comorbid depression, as generalized anxiety with comorbid depression conveys the greatest suicide risk. 1 The presence of anhedonia suggests possible depressive features requiring additional intervention. 4

Involve parents in assessment but interview the adolescent separately about appearance concerns, as parents may be engaging in "family accommodation" behaviors that perpetuate BDD. 1 Parents often provide excessive reassurance or facilitate avoidance, unintentionally fueling the disorder. 1

Common Pitfalls to Avoid

Do not provide reassurance about the adolescent's appearance or attempt to challenge their beliefs during initial assessment—this will be perceived as dismissive and damage therapeutic rapport. 1

Do not misdiagnose BDD as social anxiety disorder alone, which occurs frequently and leads to suboptimal treatment. 1 While these conditions can coexist, the face-hiding behavior suggests appearance-related preoccupation requiring BDD-specific intervention. 1

Avoid benzodiazepines for routine treatment due to addiction potential in adolescents. 3

Do not use paroxetine or fluoxetine as first-line options due to higher adverse effect rates. 3

Monitoring and Duration

Continue treatment for at least 4-12 months after symptom remission for a first episode. 2

Use validated outcome measures at every session to monitor progress: 3

  • Liebowitz Social Anxiety Scale (LSAS) or Social Phobia Inventory (SPIN) for social anxiety 3
  • Yale-Brown Obsessive Compulsive Scale modified for BDD (BDD-YBOCS) if BDD is present 3

Monitor medication response carefully, as adolescents may respond differently than adults to psychotropic medications. 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment of Social Anxiety Disorder in Adolescents

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment for Social Anxiety Disorder and OCD

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Anhedonia and Depressive Disorders.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.